Pipeline for Ear, Nose and Throat (ENT) Diseases
Lyra’s initial product candidates are focused on rhinologic diseases to provide medicine directly to sinonasal tissues that are not accessible with conventional therapeutic approaches. Our lead product candidate, LYR-210, is entering Phase 2 for chronic rhinosinusitis (CRS). Additional rhinologic indications include refractory CRS patients who have undergone sinus surgery, as well as other CRS indications. Lyra’s R&D pipeline includes other ENT diseases. Lyra has royalty-free, global rights to all product candidates across all indications.